759 related articles for article (PubMed ID: 12838524)
1. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
[TBL] [Abstract][Full Text] [Related]
2. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
3. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
4. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study.
Rakshi JS; Pavese N; Uema T; Ito K; Morrish PK; Bailey DL; Brooks DJ
J Neural Transm (Vienna); 2002 Dec; 109(12):1433-43. PubMed ID: 12486484
[TBL] [Abstract][Full Text] [Related]
6. A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study.
Whone AL; Bailey DL; Remy P; Pavese N; Brooks DJ
J Nucl Med; 2004 Jul; 45(7):1135-45. PubMed ID: 15235059
[TBL] [Abstract][Full Text] [Related]
7. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
8. Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease.
Dietz M; Harder S; Graff J; Künig G; Vontobel P; Leenders KL; Baas H
Clin Pharmacol Ther; 2001 Jul; 70(1):33-41. PubMed ID: 11452242
[TBL] [Abstract][Full Text] [Related]
9. Do dopamine agonists or levodopa modify Parkinson's disease progression?
Marek K; Jennings D; Seibyl J
Eur J Neurol; 2002 Nov; 9 Suppl 3():15-22. PubMed ID: 12464117
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
[TBL] [Abstract][Full Text] [Related]
11. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
[TBL] [Abstract][Full Text] [Related]
12. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
[TBL] [Abstract][Full Text] [Related]
13. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
[TBL] [Abstract][Full Text] [Related]
14. Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.
Storch A; Wolz M; Beuthien-Baumann B; Löhle M; Herting B; Schwanebeck U; Oehme L; van den Hoff J; Perick M; Grählert X; Kotzerke J; Reichmann H
Neurology; 2013 May; 80(19):1754-61. PubMed ID: 23576623
[TBL] [Abstract][Full Text] [Related]
15. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
[TBL] [Abstract][Full Text] [Related]
16. Chronic exposure to dopamine agonists affects the integrity of striatal D
Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
[TBL] [Abstract][Full Text] [Related]
17. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease.
Broussolle E; Dentresangle C; Landais P; Garcia-Larrea L; Pollak P; Croisile B; Hibert O; Bonnefoi F; Galy G; Froment JC; Comar D
J Neurol Sci; 1999 Jul; 166(2):141-51. PubMed ID: 10475108
[TBL] [Abstract][Full Text] [Related]
18. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
19. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
[TBL] [Abstract][Full Text] [Related]
20. Ropinirole therapy for Parkinson's disease.
Pahwa R; Lyons KE; Hauser RA
Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]